Characterization of novel bacteriophage PSKP16 and its therapeutic potential against β-lactamase and biofilm producer strain of K2-Hypervirulent Klebsiella pneumoniae pneumonia infection in mice model.
Bacteriophage
Biofilm
Hypervirulent
Klebsiella pneumoniae
Mice model
β-lactamase
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
23 08 2023
23 08 2023
Historique:
received:
22
04
2023
accepted:
14
08
2023
medline:
25
8
2023
pubmed:
24
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Severe infections caused by β- lactamase producers, hypervirulent Klebsiella pneumoniae (BhvKp) with K2 serotype, highlight emergency need for new therapeutic strategies against this pathogen. We aimed to assess the efficacy of a novel phage, PSKP16, in the treating of pneumonia induced by BhvKp in mice models. Genome sequences of PSKP16 were analyzed, and associated information can be found in NCBI. We applied treatment in two ways: by using mice for immediate and delayed treatments. Moreover, acute pneumonia obtained by BhvKp with intranasal method, was characterized in terms of histopathology of pulmonary lesions, biomarkers of inflammation level, leukocytes cells infiltration extent in mice, and was assessed treatment of them with PSKP16 multiplicity of infection (MOI: 10), either individually or in combination with gentamicin. Assessment of the ability of PSKP16 to inhibit BhvKp biofilm was studied. PSKP16 was associated with the Drexlerviridae family, and had a genome size of 46,712 bp, and 67 predicted ORFs. Herein, prompt phage administration's efficacy to decrease bacterial load and improve the survival rate in pneumonia models was faster than the synergism model with delay, but both almost displayed similar endpoints. The distribution of BhvKp strains in the lung was consistent with the histopathological findings, simultaneous inflammation, and level of serum tumor necrosis factor-α (TNF α). The phage treatment presented a lack of severe lesions and alveolar edema, reduction of inflammatory cell infiltration, which not only was it not associated with an over-inflammation but also provided a faster correction of blood cell count abnormalities compared to gentamicin. Phage with a high concentration in in vitro model effectively eliminated biofilms. It is essential to raise clinical awareness and management of BhvKp infections, signaled as the next superbug in waiting. The results of our study underscore the importance of PSKP16 as a phage with promising therapeutic potential in treating BhvKp-induced pneumonia.
Sections du résumé
BACKGROUND
Severe infections caused by β- lactamase producers, hypervirulent Klebsiella pneumoniae (BhvKp) with K2 serotype, highlight emergency need for new therapeutic strategies against this pathogen. We aimed to assess the efficacy of a novel phage, PSKP16, in the treating of pneumonia induced by BhvKp in mice models.
METHOD
Genome sequences of PSKP16 were analyzed, and associated information can be found in NCBI. We applied treatment in two ways: by using mice for immediate and delayed treatments. Moreover, acute pneumonia obtained by BhvKp with intranasal method, was characterized in terms of histopathology of pulmonary lesions, biomarkers of inflammation level, leukocytes cells infiltration extent in mice, and was assessed treatment of them with PSKP16 multiplicity of infection (MOI: 10), either individually or in combination with gentamicin. Assessment of the ability of PSKP16 to inhibit BhvKp biofilm was studied.
RESULTS
PSKP16 was associated with the Drexlerviridae family, and had a genome size of 46,712 bp, and 67 predicted ORFs. Herein, prompt phage administration's efficacy to decrease bacterial load and improve the survival rate in pneumonia models was faster than the synergism model with delay, but both almost displayed similar endpoints. The distribution of BhvKp strains in the lung was consistent with the histopathological findings, simultaneous inflammation, and level of serum tumor necrosis factor-α (TNF α). The phage treatment presented a lack of severe lesions and alveolar edema, reduction of inflammatory cell infiltration, which not only was it not associated with an over-inflammation but also provided a faster correction of blood cell count abnormalities compared to gentamicin. Phage with a high concentration in in vitro model effectively eliminated biofilms.
CONCLUSION
It is essential to raise clinical awareness and management of BhvKp infections, signaled as the next superbug in waiting. The results of our study underscore the importance of PSKP16 as a phage with promising therapeutic potential in treating BhvKp-induced pneumonia.
Identifiants
pubmed: 37612659
doi: 10.1186/s12866-023-02979-7
pii: 10.1186/s12866-023-02979-7
pmc: PMC10464470
doi:
Substances chimiques
Gentamicins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
233Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Future Microbiol. 2012 Jun;7(6):669-71
pubmed: 22702521
Int J Infect Dis. 2015 Aug;37:107-12
pubmed: 26141415
Front Microbiol. 2014 Feb 18;5:51
pubmed: 24600439
Microbiol Spectr. 2022 Oct 26;10(5):e0235822
pubmed: 36165773
Cell Host Microbe. 2019 Jun 12;25(6):803-814.e5
pubmed: 31175044
Front Microbiol. 2019 Dec 03;10:2768
pubmed: 31849905
Microbiol Mol Biol Rev. 2016 Jun 15;80(3):629-61
pubmed: 27307579
Clin Infect Dis. 2014 Jan;58(2):225-32
pubmed: 24099919
Antimicrob Agents Chemother. 2004 Sep;48(9):3343-8
pubmed: 15328095
J Appl Microbiol. 2011 Jul;111(1):1-7
pubmed: 21410851
J Infect Dis. 2010 Apr 1;201(7):1096-104
pubmed: 20196657
Lancet Infect Dis. 2004 Sep;4(9):544-5
pubmed: 15336219
J Pathog. 2016;2016:4065603
pubmed: 26942013
J Infect Dis. 2016 Feb 15;213(4):649-58
pubmed: 26347570
PLoS Pathog. 2018 Oct 1;14(10):e1007338
pubmed: 30273394
CMAJ. 2022 May 9;194(18):E645-E648
pubmed: 35534028
BMC Microbiol. 2020 Jun 1;20(1):141
pubmed: 32487015
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Appl Environ Microbiol. 2014 Feb;80(4):1469-76
pubmed: 24362424
Ther Adv Infect Dis. 2016 Feb;3(1):15-21
pubmed: 26862399
Virulence. 2014 Jan 1;5(1):226-35
pubmed: 23973944
BMC Microbiol. 2022 May 7;22(1):124
pubmed: 35525944
PLoS One. 2019 Jan 11;14(1):e0210218
pubmed: 30633757
Int J Syst Evol Microbiol. 2002 Mar;52(Pt 2):531-47
pubmed: 11931166
Sci Rep. 2018 Dec 17;8(1):17904
pubmed: 30559386
Vet Clin Pathol. 2008 Dec;37(4):373-84
pubmed: 19055571
PLoS Comput Biol. 2022 Nov 30;18(11):e1010746
pubmed: 36449520
Virol J. 2013 Mar 28;10:100
pubmed: 23537199
Infect Drug Resist. 2018 Oct 10;11:1645-1658
pubmed: 30349322
Microorganisms. 2021 Jan 20;9(2):
pubmed: 33498243
Infect Chemother. 2019 Sep 25;:
pubmed: 31782273
Scientifica (Cairo). 2014;2014:581639
pubmed: 25031881
Antimicrob Agents Chemother. 2014 Jul;58(7):4005-13
pubmed: 24798268
Virol J. 2021 Jan 6;18(1):9
pubmed: 33407669
Crit Care Med. 2015 Jun;43(6):e190-8
pubmed: 25803649
Microorganisms. 2021 Mar 21;9(3):
pubmed: 33801047
Vet Radiol Ultrasound. 2008 May-Jun;49(3):249-55
pubmed: 18546780
PLoS Comput Biol. 2017 Sep 12;13(9):e1005697
pubmed: 28898249
Front Microbiol. 2021 Apr 22;12:674068
pubmed: 33968007
mSystems. 2020 Feb 4;5(1):
pubmed: 32019835
Chest. 1995 Nov;108(5):1303-14
pubmed: 7587434
Front Vet Sci. 2021 Jul 22;8:651202
pubmed: 34368269
J Infect Dis. 2010 Jan 15;201(2):264-71
pubmed: 20001604
Res Microbiol. 2011 Oct;162(8):798-806
pubmed: 21782936
AIMS Microbiol. 2017 Mar 31;3(2):186-226
pubmed: 31294157
Sci Rep. 2020 Apr 3;10(1):5891
pubmed: 32246126
Front Microbiol. 2020 Mar 17;11:436
pubmed: 32256482
Front Cell Infect Microbiol. 2021 Aug 16;11:684704
pubmed: 34485172
Surg Infect (Larchmt). 2018 Nov/Dec;19(8):737-744
pubmed: 30256176
Open Forum Infect Dis. 2018 Mar 23;5(4):ofy064
pubmed: 29687015
Int J Mol Sci. 2022 Apr 21;23(9):
pubmed: 35562968
Emerg Infect Dis. 2012 Sep;18(9):1503-7
pubmed: 22932472
J Intern Med. 2020 Mar;287(3):283-300
pubmed: 31677303
Fiziol Zh (1994). 2009;55(3):109-17
pubmed: 19526863
Ann Clin Microbiol Antimicrob. 2020 Sep 2;19(1):40
pubmed: 32878641
Biofouling. 2010 Aug;26(6):729-37
pubmed: 20711894
Adv Virus Res. 2012;82:1-32
pubmed: 22420849
J Gen Physiol. 1939 Jan 20;22(3):365-84
pubmed: 19873108
Virology. 1956 Dec;2(6):719-36
pubmed: 13392519
Sci Rep. 2021 Sep 29;11(1):19393
pubmed: 34588479
Microb Pathog. 2021 Apr;153:104799
pubmed: 33609650
J Glob Antimicrob Resist. 2020 Jun;21:34-41
pubmed: 31604128
Arch Surg. 1997 Dec;132(12):1263-9; discussion 1269-70
pubmed: 9403528
Antimicrob Agents Chemother. 2019 Jul 25;63(8):
pubmed: 31182526
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
Appl Environ Microbiol. 2012 Sep;78(17):6380-5
pubmed: 22752161
PLoS One. 2017 Jul 18;12(7):e0179245
pubmed: 28719657
Pathobiol Aging Age Relat Dis. 2019 Jul 26;9(1):1647400
pubmed: 31489140
Vet Clin North Am Small Anim Pract. 2020 Mar;50(2):447-465
pubmed: 31813555
J Leukoc Biol. 2005 Aug;78(2):325-37
pubmed: 15817707
J Bacteriol. 2006 Oct;188(19):6924-31
pubmed: 16980495
Nature. 2023 Mar;615(7953):720-727
pubmed: 36922599
Antimicrob Resist Infect Control. 2019 May 16;8:76
pubmed: 31131107
Curr Pharm Biotechnol. 2010 Jan;11(1):28-47
pubmed: 20214606
mBio. 2021 Feb 23;12(1):
pubmed: 33622728
J Immunol. 2015 Feb 1;194(3):855-60
pubmed: 25596299
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 29925642
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
Virulence. 2013 Feb 15;4(2):107-18
pubmed: 23302790
Antibiotics (Basel). 2021 Jun 04;10(6):
pubmed: 34199889
Am J Transplant. 2019 Sep;19(9):2631-2639
pubmed: 31207123